Clinical impact and economic evaluation of organized HPV vaccination program in Hong Kong  by Choi, H. & Wu, J.T.
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mathematical model for the control of dengue using vaccines
. Chao1,∗, S. Halstead2, M.E. Halloran1, I. Longini3
Fred Hutchinson Cancer Research Center, Seattle, WA, USA
Dengue Vaccine Initiative, Rockville, MD, USA
University of Florida, Gainesville, FL, USA
Background: Before the widespread deployment of a new
engue vaccine, we need to consider how best to use lim-
ted supplies of vaccine, given the complex dengue transmission
ynamics and the immunological interaction among the four
engue serotypes.
Methods: We developed an individual-level simulation model
or dengue transmission in Ratchaburi Province in central Thailand,
he site of the ﬁrst double-blinded, dengue vaccine randomized
ontrol efﬁcacy trial. The model includes human mobility, a sea-
onal vector population, and the co-circulation of four dengue
erotypes in a population that matches the age and household
tructure of Ratchaburi. We used the model to investigate the best
se of vaccine to reduce the number of cases and dengue-related
ospitalizations.
Results: Simulation results indicate that vaccinating children
educesboth thenumberofdenguecasesandhospitalizationsmore
hanvaccinating the samenumberof adults, but local dengue trans-
ission can only be stopped if approximately 50-70% of children
nd adults are vaccinated. We also simulated multi-year catch-up
ampaigns to estimate their effectiveness.
Conclusion: Our model provides a coherent framework that
ntegrates the natural history and epidemiology of dengue in semi-
ural Thailand. The model can be used to plan mass vaccination
ampaigns, and it will be extended to evaluate coordinated mass
accination and vector control.
ttp://dx.doi.org/10.1016/j.ijid.2012.05.985
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accination against viral hepatitis A and B in adults aged over
0 Years – antibody persistence and immune memory
. Chlibek1,∗, J. Smetana1, V. Bostik2, M. Splino1
University of Defence, Hradec Kralove, Czech Republic
University of defence, Hradec Kralove, Czech Republic
Background: Primary vaccination with combined vaccine
gainst viral hepatitis A (VHA) and viral hepatitis B (VHB) induces
igher anti-hepatitis B surface (anti-HBs) antibody responses and
imilar anti-hepatitis A virus (anti-HAV) antibody responses in
dults aged over 40 years in comparison with concomitant mono-
alent vaccines againstVHAandVHB. Theobjectiveswere to assess,fectious Diseases 16S (2012) e158–e316 e301
in a clinical study, persistence of anti-HAV and anti-HBs antibod-
ies in adults aged over 40 years four years after primary VHA/VHB
vaccination and antibody response following a booster dose of the
vaccine.
Methods: Five hundred and ninety-six subjects aged>40 years
were vaccinated with three doses of the combined VHA/VHB vac-
cine at Months 0, 1, 6 (HAB group) or with concomitant VHA and
VHBvaccines atMonths0, 6 and0, 1, 6 (ENG+HAVandHBVX+VAQ,
respectively). Blood samples were collected one month following
primary vaccination (Month 7) and then at one-year intervals for
four years after the booster dose with the same vaccine as used for
the primary vaccination. The anti-HBs and anti-HAV antibody lev-
els were determined prior to the booster dose and at days 14 and
30 after the booster dose.
Results: At Month 7, > 97% of study subjects were seropositive
for anti-HAV antibodies in all groups analyzed. Four years after
primary vaccination, anti-HAV antibody seropositivity persisted
in >93% of study subjects, increasing to >99% after the booster
dose. At Month 7, the highest proportion of study subjects with
anti-HBs antibody levels > 10 mIU/ml was found in the HAB group
(91.7% versus 79.7% in the ENG+HAV group versus 71.0% in the
HBVX+VAQgroup). Four years after vaccination, anti-HBs antibody
levels of 10 mIU/ml persisted in 57.1% of the HAB study subjects
in comparison with 40.1% and 26.6% of the study subjects in the
ENG+HAV and HBVX+VAQ groups, respectively.
Conclusion: In the adults aged over 40 years, an adequate
anti-HAV antibody response persisted for at least four years after
vaccination and was higher and more sustained in those who
received the combined HAB vaccine.
http://dx.doi.org/10.1016/j.ijid.2012.05.986
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Clinical impact and economic evaluation of organized HPV vac-
cination program in Hong Kong
H. Choi ∗, J.T. Wu
The University of Hong Kong, Hong Kong, China
Background: Tomodel the impact of prophylactic HPV vaccines
against persistent HPV 16/18 infections on the age-speciﬁc inci-
dence of cervical cancer and to assess the associated incremental
cost-effectivenessofHPVvaccinationcompared to cytology screen-
ing only.
Methods: We developed a mathematical model to assess the
impact of adding a mass HPV vaccination program under the
current cervical screening program. Our model comprised deter-
ministic population-level dynamic and stochastic individual-level
components for the development of cervical cancer over the life-
timeof individuals.Weperformedcost-effectiveness analysis (CEA)
of organized HPV vaccination for age 12 girls at 45% coverage with
lifelong protection and 95% efﬁcacy against HPV types 16/18 per-
sistent infections in a 50-year time horizon. Sensitivity analyses on
vaccine effectiveness, vaccination coverage and inclusion of catch-
up programs were also performed.
Results: When 12-year girls were annually vaccinated at
45% coverage, the age-speciﬁc cancer incidence started to drop
substantially (40%-60%) after organized vaccination had begun
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or 40-80 years. Compared with screening only, adding vac-
ination of 12-year girls without catch-up program resulted
n incremental cost-effectiveness ratios (ICERs) ranging from
S$11732-14202/quality-adjusted life-year (QALY) for varying
he vaccination coverage from 25%-80%. The ICER was below
S$30000/QALY with the inclusion of a 5-year catch-up program
or ages 13-18 girls if the vaccination coverage among 12-year was
ower than 70-80%. These conclusions on cost-effectiveness remain
alid unless the vaccines provided only 10 years of protection. Sen-
itivity analyses show that duration of vaccine protection, presence
f cross-protection against non-targetedHPV types and cost of vac-
ines generated greater variation on the cost-effectiveness of the
rganized vaccine program.
Conclusion: Our model suggests that it would take decades for
he impact of organized HPV vaccination on age-speciﬁc cervical
ancer incidence to become apparent. The CEA suggests that HPV
accination of 12-year girls will likely be a cost-effective addition
o current cervical cancer prevention guidelines in Hong Kong, if
he vaccine provides at least 15-20 years of protection. However,
ost-effectiveness is only one of the important factors to be consid-
red when evaluating the pros and cons of a large-scale organized
PV vaccination program. Public’s acceptability and preparedness
f health professionals are also important factors to be considered.
ttp://dx.doi.org/10.1016/j.ijid.2012.05.987
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he effect of oral immunization of kwashiorkor rat model with
8-kDa Mycobacterium tuberculosis protein to induce the secre-
ion of intestinal and bronchial secretory immunoglobulin A
sIgA)
.K. Firani ∗, T.A. Wihastuti
University of Brawijaya, Malang, INA, Indonesia
Background: The incidence of tuberculosis (TB) is high on
alnutrition people. The new effective TB vaccines will be an
ssential strategy to eliminate tuberculosis. The 38-kDa Mycobac-
erium tuberculosis protein is one of the most potent immunogen.
he previous research showed that oral vaccination with 38-kDa
ycobacterium tuberculosis protein increased secretion of sIgA in
ormal rat intestinal and bronchial, however it has not been proven
et in the rat model of kwashiorkor. This study aimed to determine
hether oral immunization with 38-kDa Mycobacterium tuber-
ulosis protein could induce the sIgA secretion in intestinal and
ronchial mucosa of kwashiorkor rat model.
Methods: Rattus norvegicus rats were divided into 4 groups,
here were control group (normal rats), kwashiorkor rat models
ith low-protein diet 0%, 2% and 4%. All groups were given 38-kDa
ycobacterium tuberculosis protein with adjuvant orally, following
ith 2 booster every week. After 1 week of the second booster, rats
ere killed and intestinal andbronchialmucosawere taken for sIgA
ecretion and measured by sandwich ELISA.
Results: Mean (SD) intestinal sIgA are 261,01 (8,64); 233,3811,78); 245,60 (7,02) and 246,31 (10,86) ng/mL for the normal
roup, low-protein diet 0%, 2% and 4% respectively. Mean (SD)
ronchial sIgA are 78,13 (28,8), 19,06 (3,6); 24,96 (8,15) and 29,44
5,9) ng/mL for the normal group, low-protein diet 0%, 2% and 4%fectious Diseases 16S (2012) e158–e316
respectively. Statistical test showed there is no signiﬁcant differ-
ence of intestinal sIgA level among normal group and low protein
diet groups (p>0,05). Otherwise, in bronchial, there is a signiﬁcant
difference among normal and low protein diet groups (p<0,05),
which bronchial sIgA in groups of low-protein diet are lower than
normal group.
Conclusion: Immunizationwith38-kDa Mycobacterium tuber-
culosis protein orally can induce sIgA secretion from intestinal
kwashiorkor rat model as much as normal rat, but not in the
bronchial. It reveals that 38-kDa M. tuberculosis protein can act as
immunogenic factor in inducing intestinal humoral immunity of
kwashiorkor rat model.
http://dx.doi.org/10.1016/j.ijid.2012.05.988
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A prospective study comparing occurrence of post-vaccination
fever among Thai children given either DTwP or DTaP- based
vaccines
L. Fortuna1,∗, C. Sirivichayakul1, V. Watanaveeradej2, N.
Soonthornworasiri 3, R. Sitcharungsi1
1 Mahidol University, Bangkok, Thailand
2 Phramongkutklao Hospital, Bangkok, Thailand
3 Mahidol University, Bangkok, Thailand
Background: Post-vaccination fever is common in children
given routine immunization. There have been limited studies com-
paring onset of fever and occurrence of other adverse events in
Asian children following vaccination with whole-cell and acellular
pertussis-based vaccines.
Methods: A total of 150 healthy children aged 2 months to 49
months were enrolled in the study of which 75 received DTwP-
based (wP) vaccines and another 75 received DTaP-based (aP)
vaccines. Theprimary objectivewas to compare occurrence of fever
(T ≥ 37.8 ◦C) between the 2 groups of children. The secondary
objective was to compare occurrence of high fever (T ≥ 39 ◦C),
fussiness, prolonged crying, medical consultation including anal-
gesic/antipyretic given, lost sleep of parents and child, missed days
from work for parents and other adverse events between the 2
groups. Parents recorded their observations in a study diary within
72hours following vaccination. Completed diaries were returned
by mail. However, for parents who were unable to do so, data was
taken by telephone interview along with review of the study diary.
Results: A total of 140 out of 150 study participants were
included in the analysis - 72 (wP group) and 68 (aP goup). There
were 77 males (55%) and 63 females (45%) with a median age of
4 months; IQR 2 - 6. The median weight was 7.1 kg; IQR 5.6 - 8.7.
Twenty children developed fever (T ≥ 37.8 ◦C) within 4hours fol-
lowing vaccination ofwhich 17/72 (23.6%)were from thewP group
and 3/68 (4.4%) were from the aP group (p-value =0.001). More
children [30/63 or 47.6%] in wP group developed infant fussiness
comparedwith those in aP group [16/68 or 23.5%] (p-value =0.007).
Children who received wP vaccines [40/72 or 55.5%] signiﬁcantly
had higher incidence of swelling on injection site compared with
those who received aP vaccines [5/68 or 7.4%](p-value <0.001).
Conclusion: Most of the children who developed fever (T ≥
37.8 ◦C)within 4hours following vaccination receivedwP vaccines.
